Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats

Liver fibrosis is a serious health problem which is a critical cause of morbidity and mortality worldwide. It is the main complication of untreated chronic inflammatory liver diseases which can progress to liver cirrhosis, hepatocellular carcinoma, and finally death. Coagulation cascade plays a mech...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2019-08, Vol.231, p.116522-116522, Article 116522
Main Authors: Mahmoud, Nesreen Ishak, Messiha, Basim A.S., Salehc, Ibrahim G., Abo-Saif, Ali A., Abdel-Bakky, Mohamed S.
Format: Article
Language:English
Subjects:
Activation
Anticoagulants
Arteriosclerosis
Atherosclerosis
Bile
Carbon tetrachloride
Cirrhosis
Clopidogrel
Coagulation
Collagen
Dabigatran
Drugs
Fibrin
Fibrosis
Hepatocellular carcinoma
Inflammatory diseases
Inhibition
Liver
Liver cirrhosis
Liver diseases
Liver fibrosis
Markers
Morbidity
Neutropenia
Oral administration
Pathogenesis
Platelets
Prothrombin
Thrombin
Tissue factor
Tissues
Transforming growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liver fibrosis is a serious health problem which is a critical cause of morbidity and mortality worldwide. It is the main complication of untreated chronic inflammatory liver diseases which can progress to liver cirrhosis, hepatocellular carcinoma, and finally death. Coagulation cascade plays a mechanistic role in the pathogenesis of different chronic inflammatory disease including atherosclerosis, stroke, and tissue fibrosis. The current study was designed to investigate the effect of inhibition of coagulation cascade on carbon tetrachloride (CCl4)-induced liver fibrosis in rats. The study was conducted in rats. Rats were treated with CCl4 subcutaneously for 6 consecutive weeks to determine the onset of coagulation system activation in relation to development of fibrosis. To investigate the effects of coagulation system inhibition in CCl4-induced liver fibrosis, the anticoagulants drugs dabigatran and clopidogrel were administrated orally concurrently with CCl4 treatment. The results of our study revealed that during the first week, there were significant elevations of fibrin, tissue factor expressions, and prothrombin time (PT) coupled with neutropenia without significant changes in liver fibrosis markers such as TGF-β, α-SMA and collagen deposition. Starting from the second week, tissue injury markers including the oxidative, inflammatory and fibrosis markers as well as histopathological changes became evident progressively. Intriguingly, dabigatran and clopidogrel significantly normalized the biochemical and pathological changes. In conclusion, activation of coagulation cascade is a triggering stimulus in the initiation of CCl4-induced liver fibrosis and the anticoagulant drugs may exert promising anti-fibrotic effect. [Display omitted]
ISSN:0024-3205
1879-0631
DOI:10.1016/j.lfs.2019.05.078